Effect of Sotagliflozin on Cardiovascular Events in Participants With Type 2 Diabetes Post Worsening Heart Failure (SOLOIST-WHF Trial)

Exclusion Criteria

• •Age \< 18 years or \> 85 years.
• •Worsening heart failure attributed to other causes such as pulmonary embolism, stroke, heart attack.
• •Cardiac surgery or coronary procedure within 1 month or planned during study.
• •Lower extremity complications (such as skin ulcer, infection, osteomyelitis, and gangrene) identified during screening and requiring treatment at randomization.
• •Planning to start a sodium-glucose linked transporter-2 (SGLT2) inhibitor during the study.
• •Acute coronary syndromes within 3 months prior to Randomization.
• •Hemodynamically significant uncorrected primary valvular disease.
• •Significant pulmonary disease contributing substantially to the participant's dyspnea.
• •End stage Heart Failure.
• •History of diabetic ketoacidosis (DKA) or nonketotic hyperosmolar coma within 3 months prior to screening.
• •History of stroke within 3 months prior to randomization.
• •History of dialysis within 1 year prior to randomization.
• •History of solid organ transplant or on a transplant list (if heart transplant, defined as status 1 transplant).
• •Severe kidney disease as defined by glomerular filtration rate (eGFR) \<30 milliliter per minute per 1.72 meter square (mL/min/1.73 m\^2).
• •Pregnancy.
• •The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.